Taxpayers and patients spent >$500 million in 3 years on a cancer drug olaratumab that ultimately failed. OncoPower wants to change that with patient and physician centered tools that increase awareness of low-cost practices and mitigate the financial toxicity of cancer treatments that offer no clinical benefit.
Our tool offers data-driven patient education on high-impact interventions prior to care plan decisions. It facilitates patient and provider engagement regarding the real value of treatments and thoroughly assesses alternative options. Our contract physicians empower patients using clinical pathways for their treatment, a modality that facilitates consideration of all evidence-based options.